Triptolide protects against white matter injury induced by chronic cerebral hypoperfusion in mice

Acta Pharmacol Sin. 2022 Jan;43(1):15-25. doi: 10.1038/s41401-021-00637-0. Epub 2021 Apr 6.

Abstract

White matter injury is the major pathological alteration of subcortical ischemic vascular dementia (SIVD) caused by chronic cerebral hypoperfusion. It is characterized by progressive demyelination, apoptosis of oligodendrocytes and microglial activation, which leads to impairment of cognitive function. Triptolide exhibits a variety of pharmacological activities including anti-inflammation, immunosuppression and antitumor, etc. In this study, we investigated the effects of triptolide on white matter injury and cognitive impairments in mice with chronic cerebral hypoperfusion induced by the right unilateral common carotid artery occlusion (rUCCAO). We showed that triptolide administration alleviated the demyelination, axonal injury, and oligodendrocyte loss in the mice. Triptolide also improved cognitive function in novel object recognition test and Morris water maze test. In primary oligodendrocytes following oxygen-glucose deprivation (OGD), application of triptolide (0.001-0.1 nM) exerted concentration-dependent protection. We revealed that the protective effect of triptolide resulted from its inhibition of oligodendrocyte apoptosis via increasing the phosphorylation of the Src/Akt/GSK3β pathway. Moreover, triptolide suppressed microglial activation and proinflammatory cytokines expression after chronic cerebral hypoperfusion in mice and in BV2 microglial cells following OGD, which also contributing to its alleviation of white matter injury. Importantly, mice received triptolide at the dose of 20 μg·kg-1·d-1 did not show hepatotoxicity and nephrotoxicity even after chronic treatment. Thus, our results highlight that triptolide alleviates whiter matter injury induced by chronic cerebral hypoperfusion through direct protection against oligodendrocyte apoptosis and indirect protection by inhibition of microglial inflammation. Triptolide may have novel indication in clinic such as the treatment of chronic cerebral hypoperfusion-induced SIVD.

Keywords: chronic cerebral hypoperfusion; microglial activation; oligodendrocyte; right unilateral common carotid artery occlusion (rUCCAO); triptolide; white matter injury.

MeSH terms

  • Animals
  • Cognitive Dysfunction / drug therapy*
  • Cognitive Dysfunction / metabolism
  • Cognitive Dysfunction / pathology
  • Diterpenes / administration & dosage
  • Diterpenes / pharmacology*
  • Dose-Response Relationship, Drug
  • Epoxy Compounds / administration & dosage
  • Epoxy Compounds / pharmacology
  • Injections, Intraperitoneal
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Molecular Structure
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / pharmacology*
  • Phenanthrenes / administration & dosage
  • Phenanthrenes / pharmacology*
  • Structure-Activity Relationship
  • White Matter / drug effects*
  • White Matter / metabolism
  • White Matter / pathology

Substances

  • Diterpenes
  • Epoxy Compounds
  • Neuroprotective Agents
  • Phenanthrenes
  • triptolide